We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ALNOV market cap is 39.48M. The company's latest EPS is GBP and P/E is N/A.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 12.64M | 277.2M | 95.78M | 22.49M | 11.58M |
| Operating Income | -3.59M | 167.52M | -7.79M | -33.21M | -30.34M |
| Net Income | -5.75M | 132.42M | -9.73M | -25.73M | -28.29M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 26.53M | 234.28M | 183.7M | 140.9M | 133.82M |
| Total Liabilities | 14.07M | 83.57M | 41.88M | 25.69M | 46.57M |
| Total Equity | 12.46M | 150.71M | 141.82M | 115.22M | 87.24M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -940k | 102.98M | 15.69M | -13.73M | -24.99M |
| Investing | -1.05M | -7.97M | -5.03M | -577k | -13.94M |
| Financing | 2.5M | -5.04M | -599k | -516k | -3.97M |
| Market Cap | 39.48M |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 70.63M |
| Average Volume (1 week) | 309.71k |
| Average Volume (1 Month) | 531.98k |
| 52 Week Change | 27.05% |
| 52 Week High | 0.995 |
| 52 Week Low | 0.42 |
| Spread (Intraday) | 0.02 (2.86%) |
| Company Name | Novacyt |
| Address |
13 avenue morane saulnier velizy-villacoublay, yvelines 78140 |
| Website | https://www.novacyt.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
